HTA Quarterly | Spring 2020

By Xcenda |

In this issue, our editors examine the patient voice in HTA, updates to the ICER and NICE frameworks, and the changing healthcare landscape in India with the adoption of their own HTA. 

Heard on the Street

“CADTH is pleased to announce the formation of the Pharmaceutical Advisory Committee, a new advisory body that will provide strategic advice to CADTH on drug-related issues and topics. This committee has been formed through the merger of the Drug Policy Advisory Committee and the pCODR [pan-Canadian Oncology Drug Review] Advisory Committee. Consolidation of these committees will offer efficiency for both CADTH and the participating jurisdictions. CADTH wishes to thank all jurisdictional representatives who served on the previous advisory committees for their contributions.”

– CADTH (Canadian Agency for Drugs and Technologies in Health) news release
CADTH Pharmaceutical Reviews Update—Issue 12

HTA by the Numbers


Haute Autorité de Santé (HAS) published an action plan for innovative medicines that contains 6 points. The aim of this action plan is to appropriately balance the need for access to potentially high-value, innovative therapies which often have uncertainty around the clinical benefit as a result of short clinical developments, on small samples of patients. These 6 points include:

  1. Make conditional opinions, time to resolve uncertainties
  2. Track medications in real life to verify initial promises
  3. Strengthen the agility of HAS to better support innovation
    1. Focus on high added-value assessments
    2. Develop early meetings to support clinical developments
    3. Promote accelerated (so-called “fast-tracking”) assessment procedures
    4. Improve collective efficiency
  4. Systematically involve patients and users
  5. Strengthen transparency
    1. On time
    2. On post-registration studies
  6. Strengthen European cooperation to pool knowledge

Source: La HAS présente son plan d’action pour les médicaments innovants